Trial reportMedical science monitor : international medical journal of experimental and clinical research2025
Enhanced Eustachian Tube Function and Hearing Recovery with Combined Balloon Dilatation and Tympanic Membrane Catheterization in Secretory Otitis Media.
Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Secretory otitis media (SOM), a common otorhinolaryngological disorder, impairs hearing and quality of life. Eustachian tube balloon dilatation (ETBD) is increasingly used, and its combination with tympanic membrane catheterization (TMC) may enhance outcomes. This study compared ETBD alone with ETBD combined with TMC in adult SOM. MATERIAL AND METHODS Ninety patients (110 ears) with SOM were randomized equally into 2 groups between September 2020 and September 2022. The balloon-only group received ETBD, while the balloon plus catheterization group underwent ETBD combined with TMC. Clinical efficacy was defined as symptom resolution, effusion clearance, and hearing recovery. Eustachian tube function was assessed by manometry (R score) and Eustachian Tube Score (ETS). The Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) assessed symptom burden of ear pressure, pain, tinnitus, and muffled hearing. Serum procalcitonin, high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) were measured by ELISA. Hearing thresholds were determined using pure-tone audiometry. Six-month recurrence was defined as the reappearance of effusion or symptoms following tympanic membrane healing, determined by otoscopy, tympanometry, and symptom verification. RESULTS The effective rate was significantly higher in the ETBD combined with TMC group (95.56%) than the ETBD-only group (77.78%, P<0.05). Combination therapy yielded greater improvements in R scores, ETS, ETDQ-7, and hearing thresholds, and greater reductions in procalcitonin, hs-CRP, and IL-6 (all P<0.05). Recurrence was lower (4.44% vs 22.22%, P<0.05), with comparable complication rates (P>0.05). CONCLUSIONS ETBD combined with TMC significantly enhanced ET function, symptom relief, inflammatory control, and hearing recovery while reducing recurrence, supporting its adoption in adult SOM management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.